Sirosis Hepatis - Reversibel atau Irreversibel?

Bernard Jonathan Christian Yong, Marco Vidor

Abstract

Sirosis hepatis adalah tahap akhir penyakit hati dengan berbagai penyebab, antara lain kelainan  metabolik atau infeksi hepatitis B dan hepatitis C. Hingga saat ini, sirosis hepatis diyakini sebagai proses tidak reversibel, yang berujung dengan transplantasi hati. Namun, seiring dengan perkembangan teknologi dan pemahaman tentang patogenesis, sirosis hepatis mungkin bersifat reversibel.

 

Liver cirrhosis is a final stage of liver disease with many etiologies, i.e. metabolic disorder or infection like type B hepatitis and type C hepatitis. Liver cirrhosis is still being considered as an irreversible disease, which leads to liver transplantation. But as far as the development of technology and knowledge of liver cirrhosis pathogenesis, liver cirrhosis might be considered as a reversible process.

Full Text:

PDF

References

Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: A systematic analysis. BMC Medicine 2014;12:145. doi: 10.1186/s12916-014-0145-y

Darmayasa PB, Somayana G. Hubungan antara derajat keparahan sirosis hepatis dengan kejadian peritonitis bakterial spontan. E-Jurnal Medika Udayana.2018;7(9):1-6.

Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol. WJG. 2014;20(23):7312. doi: 10.3748/wjg.v20.i23.7312

Sharma B, John S. Hepatic cirrhosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publ; 2021 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482419/

Safadi R, Friedman SL. Hepatic fibrosis -- role of hepatic stellate cell activation. MedGenMed. 2002;4:27.

Braet F, Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: A review. Comp Hepatol. 2002;1:1.

Yokomori H, Oda M, Yoshimura K, Hibi T. Recent advances in liver sinusoidal endothelial ultrastructure and fine structure immunocytochemistry. Micron. 2012;43:129–34.

Kolios G, Valatas V, Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol. 2006;12:7413–20

Thieringer F, Maass T, Czochra P, Klopcic B, Conrad I, Friebe D, et al. Spontaneous hepatic fibrosis in transgenic mice overexpressing PDGF-A. Gene. 2008;423(1):23-8.

Kirmaz C, Terzioglu E, Topalak O, Bayrak P, Yilmaz O, Ersoz G, et al. Serum transforming growth factor-beta1(TGF-beta1) in patients with cirrhosis, chronic hepatitis B and chronic hepatitis C [corrected]. Eur Cytokine Netw. 2004;15:112-6.

Ogawa T, Kawada N, Ikeda K. Effect of natural interferon α on proliferation and apoptosis of hepatic stellate cells. Hepatol Internat. 2009;3(3):497-503. doi: 10.1007/s12072-009-9129-y

Rao H‐Y, Wei L, Wang J‐H, Fei R, Jiang D, Zhang Q, Chen H‐S, Cong X. Inhibitory effect of human interferon‐beta‐1a on activated rat and human hepatic stellate cells. J Gastroenterol Hepatol. 2010;25:1777-84. https://doi.org/10.1111/j.1440-1746.2010.06264.x

Baroni GS, D'Ambrosio L, Curto P, Casini A, Mancini R, Jezequel AM, et al. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology 1996;23:1189-99. https://doi.org/10.1002/hep.510230538

Gieling R, Wallace K, Han Y. Interleukin-1 participates in the progression from liver injury to fibrosis. Am J Physiol - Gastrointestinal and Liver Physiology. 2009;296(6):1324-31.

Hang LJ, Zheng WD, Chen YX, Huang YH, Chen ZX, Zhang SJ, et al. Antifibrotic effects of interleukin-10 on experimental hepatic fibrosis. Hepatogastroenterol. 2007;54(79):2092-8. PMID: 18251166

Borthwick L, Wynn T, Fisher A. Cytokine mediated tissue fibrosis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2013;1832(7):1049-60. https://doi.org/10.1016/j.bbadis.2012.09.014

Sun M, Kisseleva T. Reversibility of liver fibrosis. Clin Res Hepatol Gastroenterol. 2015;39:60-3. https://doi.org/10.1016/j.clinre.2015.06.015

Kisseleva T, Cong M, Paik Y, Scholten D, Jiang C, Benner C, et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci. 2012;109(24):9448-53. https://doi.org/10.1073/pnas.1201840109

Jung Y, Yim H. Reversal of liver cirrhosis: Current evidence and expectations. Korean J Internal Med. 2017;32(2):213-28. https://doi.org/10.3904/kjim.2016.268

Dienstag J, Goldin R, Heathcote E, Hann H, Woessner M, Stephenson S, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124(1):105-17. Doi: 10.1053/gast.2003.50013

Chang T, Liaw Y, Wu S, Schiff E, Han K, Lai C, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52(3):886-93. https://doi.org/10.1002/hep.23785

Lee YA, Friedman SL. Reversal, maintenance or progression: What happens to the liver after a virologic cure of hepatitis C? Antiviral Res. 2014;107:23-30. https://doi.org/10.1016/j.antiviral.2014.03.012

George S, Bacon B, Brunt E, Mihindukulasuriya K, Hoffmann J, Di Bisceglie A. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients. Hepatology 2008;49(3):729-38. doi: 10.1002/hep.22694

Verrill C, Markham H, Templeton A, Carr N, Sheron N. Alcohol-related cirrhosis-early abstinence is a key factor in prognosis, even in the most severe cases. Addiction. 2009;104(5):768-74. DOI: 10.1111/j.1360-0443.2009.02521.x

Promrat K, Kleiner D, Niemeier H, Jackvony E, Kearns M, Wands J, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2009;51(1):121-9. DOI: 10.1002/hep.23276

Refbacks

  • There are currently no refbacks.